Literature DB >> 26985596

Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Crystal R Leibrand1, Douglas K Price1, William D Figg1.   

Abstract

Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.

Entities:  

Keywords:  Androgen receptor; prostate cancer; splice variants

Mesh：

Substances：

Year:  2016        PMID： 26985596      PMCID： PMC4910935          DOI： 10.1080/15384047.2016.1156274

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  19 in total

1.  Commentary on "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.

Authors:  Ganesh S Palapattu
Journal:  Urol Oncol       Date:  2016-03-07       Impact factor: 3.498

2.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Authors:  Ziyang Yu; Sen Chen; Adam G Sowalsky; Olga S Voznesensky; Elahe A Mostaghel; Peter S Nelson; Changmeng Cai; Steven P Balk
Journal:  Clin Cancer Res       Date:  2014-01-21       Impact factor: 12.531

3.  NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.

Authors:  Nagalakshmi Nadiminty; Ramakumar Tummala; Chengfei Liu; Wei Lou; Christopher P Evans; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2015-06-08       Impact factor: 6.261

4.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Authors:  M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis
Journal:  Ann Oncol       Date:  2015-06-27       Impact factor: 32.976

5.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.

Authors:  Duo Xu; Yang Zhan; Yanfeng Qi; Bo Cao; Shanshan Bai; Wei Xu; Sanjiv S Gambhir; Peng Lee; Oliver Sartor; Erik K Flemington; Haitao Zhang; Chang-Deng Hu; Yan Dong
Journal:  Cancer Res       Date:  2015-06-09       Impact factor: 12.701

6.  Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Authors:  Meng-Lei Zhu; Craig M Horbinski; Mark Garzotto; David Z Qian; Tomasz M Beer; Natasha Kyprianou
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

7.  Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.

Authors:  Tristan M Sissung; Romano Danesi; Douglas K Price; Seth M Steinberg; Ronald de Wit; Muhammad Zahid; Nilesh Gaikwad; Ercole Cavalieri; William L Dahut; Dan L Sackett; William D Figg; Alex Sparreboom
Journal:  Mol Cancer Ther       Date:  2008-01-09       Impact factor: 6.261

8.  Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.

Authors:  Andrew K Kwegyir-Afful; Senthilmurugan Ramalingam; Puranik Purushottamachar; Vidya P Ramamurthy; Vincent C O Njar
Journal:  Oncotarget       Date:  2015-09-29

9.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.

Authors:  Guanyi Zhang; Xichun Liu; Jianzhuo Li; Elisa Ledet; Xavier Alvarez; Yanfeng Qi; Xueqi Fu; Oliver Sartor; Yan Dong; Haitao Zhang
Journal:  Oncotarget       Date:  2015-09-15

10.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.

Authors:  Bo Cao; Yanfeng Qi; Guanyi Zhang; Duo Xu; Yang Zhan; Xavier Alvarez; Zhiyong Guo; Xueqi Fu; Stephen R Plymate; Oliver Sartor; Haitao Zhang; Yan Dong
Journal:  Oncotarget       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.